These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 17437208

  • 1. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins.
    Christian MS, Brent RL, Calda P.
    J Matern Fetal Neonatal Med; 2007 Feb; 20(2):89-112. PubMed ID: 17437208
    [Abstract] [Full Text] [Related]

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits.
    Cook JC, Jacobson CF, Gao F, Tassinari MS, Hurtt ME, DeSesso JM.
    Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):5-26. PubMed ID: 12852480
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice.
    Seegmiller RE, Nelson GW, Johnson CK.
    Teratology; 1983 Oct; 28(2):201-8. PubMed ID: 6648824
    [Abstract] [Full Text] [Related]

  • 5. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
    O'Brien JM.
    Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
    [Abstract] [Full Text] [Related]

  • 6. The use of progestational agents for preterm birth: lessons from a mouse model.
    Elovitz MA, Mrinalini C.
    Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
    [Abstract] [Full Text] [Related]

  • 7. Teratogen update: evaluation of the reproductive and developmental risks of caffeine.
    Christian MS, Brent RL.
    Teratology; 2001 Jul; 64(1):51-78. PubMed ID: 11410911
    [Abstract] [Full Text] [Related]

  • 8. Analysis of reproductive toxicity and classification of glufosinate-ammonium.
    Schulte-Hermann R, Wogan GN, Berry C, Brown NA, Czeizel A, Giavini E, Holmes LB, Kroes R, Nau H, Neubert D, Oesch F, Ott T, Pelkonen O, Robert-Gnansia E, Sullivan FM.
    Regul Toxicol Pharmacol; 2006 Apr; 44(3 Suppl 1):S1-76. PubMed ID: 16510221
    [Abstract] [Full Text] [Related]

  • 9. Different embryo-fetal toxicity effects for three VLA-4 antagonists.
    Crofts F, Pino M, DeLise B, Guittin P, Barbellion S, Brunel P, Potdevin S, Bergmann B, Hofmann T, Lerman S, Clark RL.
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):55-68. PubMed ID: 15098199
    [Abstract] [Full Text] [Related]

  • 10. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [Abstract] [Full Text] [Related]

  • 11. Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate.
    Hendrickx AG, Korte R, Leuschner F, Neumann BW, Poggel A, Binkerd P, Prahalada S, Günzel P.
    Teratology; 1987 Feb; 35(1):129-36. PubMed ID: 3563931
    [Abstract] [Full Text] [Related]

  • 12. Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species.
    Khera KS.
    Teratology; 1985 Feb; 31(1):129-53. PubMed ID: 3983854
    [Abstract] [Full Text] [Related]

  • 13. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
    O'Brien JM, Ho SJ, Istwan NB, Stanziano GJ, Rhea DJ, Barton JR.
    Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788
    [Abstract] [Full Text] [Related]

  • 14. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008 Feb; 27 Suppl 4():1-82. PubMed ID: 19101832
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
    Oler E, Eke AC, Hesson A.
    Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 17. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO, Stamilio DM, Macones GA, Polsky D.
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [Abstract] [Full Text] [Related]

  • 18. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S.
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [Abstract] [Full Text] [Related]

  • 19. The role of progesterone in maternal and fetal medicine.
    Di Renzo GC, Giardina I, Clerici G, Mattei A, Alajmi AH, Gerli S.
    Gynecol Endocrinol; 2012 Nov; 28(11):925-32. PubMed ID: 23057618
    [Abstract] [Full Text] [Related]

  • 20. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D, Moore RM, Mercer BM, Mansour JM, Mesiano S, Schatz F, Lockwood CJ, Moore JJ.
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.